

For Immediate Release
For Further Information Contact:
Therese Fergo at (301) 608-9292
Email: Therese@unither.com

**UNITED THERAPEUTICS CORPORATION DISCUSSES FIRST QUARTER
2001 FINANCIAL RESULTS AT DEUTSCHE BANC ALEX. BROWN'S
HEALTH CARE 2001 CONFERENCE**

Silver Spring, MD, May 9, 2001: United Therapeutics Corporation (Nasdaq: UTHR) today announced financial results for the first quarter ended March 31, 2001 prior to its presentation at the 26th Annual Deutsche Banc Alex. Brown, Health Care 2001 Conference.

"We are pleased to have ended the quarter in such strong financial condition. At March 31, 2001, United Therapeutics had \$206.4 million of cash and investments and practically no debt. Our loss of \$.46 per share is down from \$1.57 in the previous quarter and only up \$.02 from \$.44 one year ago," said Martine A. Rothblatt, Chairman and Chief Executive Officer. Ms. Rothblatt continued saying, "Although we were disappointed in April when the FDA required additional time to review our New Drug Application for Remodulin, we are optimistic that the FDA will complete its review by July 2001 and are working very hard to assist the agency toward this goal." Ms. Rothblatt further remarked, "In the first quarter, United Therapeutics completed enrollment for two phase III pivotal studies of beraprost, the only oral form of prostacyclin, for peripheral vascular disease and pulmonary arterial hypertension. The quarter was also quite busy for our telemedicine division, where we are continuing to build our capabilities and experiencing excellent growth."

Revenues during the first quarter of 2001 were \$1.5 million as compared to revenues of \$790,000 in the previous quarter and \$309,000 during the first quarter of 2000. The increase in revenues during the first quarter of 2001 was due primarily to sales by United Therapeutics' telemedicine subsidiary, Medicomp. Medicomp was acquired by United Therapeutics in December 2000 and reported sales of \$646,000 during the first quarter of 2001. Pharmaceutical sales, which include the sale of Remodulin pumps and supplies as well as arginine products, totaled \$837,000 during the first quarter of 2001.

Research and development expenses were \$8.5 million for the first quarter of 2001 as compared to \$5.8 million for the first quarter of 2000. The increase was due primarily to increased expenses related to patient enrollment in United Therapeutics' clinical trials and other research. General and administrative expenses were \$3.9 million for the three months ended March 31, 2001, as compared to \$3.8 for the three months ended March 31, 2000.

Sales and marketing expenses were \$844,000 for the first quarter of 2001 as compared to none in the first quarter of 2000. Cost of sales was \$805,000 for the first quarter of 2001 as compared to \$220,000 in the first quarter of 2000. These increases were due primarily to expanded activities associated with the newly acquired telemedicine and arginine businesses.

Interest income was \$3.3 million during the first quarter of 2001 as compared to \$1.6 million during the first quarter of 2000. This increase was attributable to an increase in the amount of cash available for investing resulting from sales of common stock since March 31, 2000, less amounts used for operations.

On December 5, 2000, United Therapeutics' Board approved a stock repurchase program for up to 3,000,000 shares of United Therapeutics' outstanding stock. The program was set to expire in May 2001, but has been extended for an additional six months. Since December 2000, United Therapeutics has purchased approximately 500,000 shares.

United Therapeutics will host a teleconference on May 10, 2001 at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-800-360-9865. A re-broadcast of the teleconference will be available for 24 hours following the teleconference by dialing 1-800-428-6051 and using access code 188043.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious disease with unique therapeutic products. United Therapeutics is a member of the Russell 3000 Index and is included in the iShares Nasdaq Biotechnology Index Fund (NBI).

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS DATA

	<u>Three months ended March 31,</u>	
	<u>2001</u>	<u>2000</u>
Revenues:		
Sales	\$ 1,262,795	\$ 259,397
Sales to affiliates	219,720	-
Grant revenue	-	50,000
Total revenues	<u>1,482,515</u>	<u>309,397</u>
Operating expenses:		
Research and development	8,468,853	5,776,749
General and administrative	3,919,999	3,801,150
Sales and marketing	844,111	-
Cost of sales	<u>805,283</u>	<u>220,283</u>
Total operating expenses	<u>14,038,246</u>	<u>9,798,182</u>
Loss from operations	(12,555,731)	(9,488,785)
Other income (expense):		
Interest income	3,284,527	1,557,858
Interest expense	(39,178)	(27,996)
Equity in loss of affiliate	(61,532)	-
Other, net	<u>(30,870)</u>	<u>47,326</u>
Total other income	<u>3,152,947</u>	<u>1,577,188</u>
Net loss before income tax	(9,402,784)	(7,911,597)
Income tax	-	-
Net loss	<u>\$ (9,402,784)</u>	<u>\$ (7,911,597)</u>
Net loss per common share - basic and diluted	<u>\$ (.46)</u>	<u>\$ (.44)</u>
Weighted average number of common shares outstanding - basic and diluted	<u>20,392,682</u>	<u>18,053,256</u>

CONSOLIDATED BALANCE SHEET DATA

	<u>March 31,</u>	<u>December 31,</u>
	<u>2001</u>	<u>2000</u>
Cash, Cash Equivalents, Marketable Investments, and Certificate of Deposit	\$206,360,946	\$215,990,326
Total Assets	\$240,998,774	\$250,644,984
Total Stockholders' Equity	\$224,791,445	\$234,737,782